Belgian biotechnology company ViroVet announced on Monday that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing in Belgium.
According to its CEO, Dr Erwin Blomsma, the company has a clear moral obligation to divert some of its activities to join forces with the COVID19 teams to offer support where necessary.
Dr Nesya Goris, Chief Development Officer and co-founder of ViroVet added: “This is within our capability, our research team has the relevant expertise and training. As our company focuses on viral diseases, our laboratories and procedures are perfectly suitable, and we are ready to help.”
The company confirms that it will continue with its outsourced studies on veterinary vaccines and antiviral drugs.
More info on ViroVet‘s website.